Eribulin in patients with Liposarcoma and Leiomyosarcoma - a retrospective single center experience
Abstract
Introduction: Soft tissue sarcomas (STS) are rare and heterogenous malignancies with a poor prognosis in advanced disease stages. Eribulin is used in metastatic Liposarcoma (LPS) patients, who have failed first line chemotherapy and has been approved for the use in patients with LPS in the United States and Europe due to its efficacy in this histological subtype in a phase III trial. We have evaluated efficacy and tolerability of eribulin in LPS and Leiomyosarcoma (LMS) patients in the routine clinical setting at our department.
Methods: In this retrospective single center analysis, efficacy and safety of eribulin were retrospectively evaluated in advanced LPS and LMS patients at the Division of Oncology, Medical University of Vienna.
Results: A total of 32 adult patients treated with eribulin were identified and included in this analysis. Overall response rate (ORR) was 9.4% for all patients, with one patient with LPS and two patients with leiomyosarcoma (LMS) showing a partial response (PR). Disease control rate (PR plus stable disease -SD) for all patients was 50% (LPS: 47.1%; LMS 53.3%). No statistically significant difference in median progression free survival (PFS) and overall survival (OS) was detected between patients with LPS and LMS (p=0.807 and p=0.519), respectively. Patients with LMS (n=2) had received fewer previous therapy lines than patients with LPS (n=14) (≤ previous treatment lines, p
The Author(s). Published by S. Karger AG, Basel
Article / Publication Details
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Comments (0)